跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 12,567 条关于
“NaV1.1 protein”
全部
12,567
临床试验
5,644
药物
1,263
机构
53
资讯
5,607
去年
Zorevunersen Receives FDA Breakthrough Therapy Designation for Dravet Syndrome
去年
Zorevunersen Shows Promising Cognitive and Behavioral Improvements in Dravet Syndrome Phase 3 Trial Analysis
2年前
Stoke Therapeutics and Biogen Initiate Phase 3 EMPEROR Trial for Zorevunersen in Dravet Syndrome
10个月前
Stoke Therapeutics Advances Phase 3 Dravet Syndrome Trial with Strong Financial Position Through 2028
2年前
Stoke Therapeutics Advances Zorevunersen for Dravet Syndrome to Phase III After FDA Lifts Clinical Hold
去年
Biogen and Stoke Therapeutics Collaborate to Advance Zorevunersen for Dravet Syndrome
去年
Encoded Therapeutics Receives FDA RMAT Designation for ETX101 Gene Therapy in Dravet Syndrome
9个月前
Encoded Therapeutics Reports 78% Seizure Reduction with ETX101 Gene Therapy in Dravet Syndrome Trial
3个月前
Developmental and Epileptic Encephalopathies Market Poised for 11.7% CAGR Growth Through 2036, Driven by Next-Generation Gene and Targeted Therapies
去年
FDA Roundup: Approvals, Breakthrough Designations, and Clinical Holds in Neurology and Rare Diseases
第 1 页,共 561 页
上一页
下一页